Neurocrine Bio. (NBIX) PT Lowered to $131 at Barclays
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $156.22 -0.22%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $136.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $183 at Morgan Stanley
- Visual Photonics Epitaxy Co Ltd (2455:TT) PT Raised to NT$846 at Macquarie
- Clear Secure Inc (YOU) PT Lowered to $45 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
